Page last updated: 2024-09-20

embelin

Description

embelin: from Embelia fruit (Myrsinaceae) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

embelin : A member of the class of dihydroxy-1,4-benzoquinones that is 2,5-dihydroxy-1,4-benzoquinone which is substituted by an undecyl group at position 3. Isolated from Lysimachia punctata and Embelia ribes, it exhibits antimicrobial, antineoplastic and inhibitory activity towards hepatitis C protease. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
RibesgenusAlso known as currant, ribes is a member of the family GROSSULARIACEAE. Oil extracted from the seeds contain GAMMA-LINOLENIC ACID.[MeSH]GrossulariaceaeA plant family of the order ROSALES, subclass Rosidae, class Magnoliopsida. They are deciduous woody shrubs with alternate leaves. The flowers are in terminal racemes with 5 petals and 5 stamens.[MeSH]
Lysimachiagenus[no description available]PrimulaceaeA plant family of the order ERICALES, class MAGNOLIOPSIDA, with flowers having both stamens and pistil, producing encapsulated fruits.[MeSH]
Embelia ribesspecies[no description available]PrimulaceaeA plant family of the order ERICALES, class MAGNOLIOPSIDA, with flowers having both stamens and pistil, producing encapsulated fruits.[MeSH]
Lysimachia punctataspecies[no description available]PrimulaceaeA plant family of the order ERICALES, class MAGNOLIOPSIDA, with flowers having both stamens and pistil, producing encapsulated fruits.[MeSH]

Cross-References

ID SourceID
PubMed CID3218
CHEMBL ID221137
CHEBI ID4778
SCHEMBL ID148744
MeSH IDM0056867

Synonyms (94)

Synonym
smr000470851
MLS000563189
BIDD:ER0529
HMS3268N13
DIVK1C_006597
KBIO1_001541
NCI60_042031
SDCCGMLS-0066817.P001
embelin, >=98% (hplc), powder
2,5-cyclohexadiene-1,4-dione, 2,5-dihydroxy-3-undecyl-
einecs 208-979-8
2,5-dihydroxy-3-undecyl-2,5-cyclohexadiene-1,4-dione
brn 1885786
p-benzoquinone, 2,5-dihydroxy-3-undecyl-
nsc 91874
SPECTRUM_001513
SPECTRUM4_001760
SPECTRUM5_000620
NCGC00025359-01
tocris-2156
NCGC00017248-01
tnp00137
BSPBIO_003531
NSC91874 ,
2,5-dihydroxy-3-undecyl-p-benzoquinone
2,5-dihydroxy-3-undecyl-1,4-benzoquinone
emberine
nsc-91874
p-benzoquinone,5-dihydroxy-3-undecyl-
2,4-dione, 2,5-dihydroxy-3-undecyl-
embelic acid
HSCI1_000123
550-24-3
embelin
NCGC00025359-03
NCGC00025359-02
KBIO2_001993
KBIOSS_001993
KBIO2_004561
KBIOGR_002240
KBIO3_002783
KBIO2_007129
SPECPLUS_000501
SPECTRUM3_001931
SPECTRUM1504074
NCGC00025359-05
NCGC00025359-04
2,5-dihydroxy-3-undecylcyclohexa-2,5-diene-1,4-dione
CHEMBL221137
chebi:4778 ,
HMS1922B07
4-08-00-02769 (beilstein handbook reference)
shc6u8f5er ,
unii-shc6u8f5er
A830443
2,5-dihydroxy-3-undecyl-[1,4]benzoquinone
HMS2271A03
AKOS016010144
CCG-39906
NCGC00017248-02
NCGC00017248-06
NCGC00017248-04
NCGC00017248-03
NCGC00017248-07
NCGC00017248-08
NCGC00017248-05
NCGC00017248-10
embelin [mi]
CS-1879
HY-17473
SCHEMBL148744
IRSFLDGTOHBADP-UHFFFAOYSA-N
mfcd00016369
DTXSID80203537
bdbm50078850
SR-01000597536-3
SR-01000597536-1
sr-01000597536
HMS3652J16
embeliaquinone
gtpl11209
ncgc00017248-12!2,5-dihydroxy-3-undecylcyclohexa-2,5-diene-1,4-dione
SW219508-1
FT-0712499
S7025
HMS3677I11
Q27068169
HMS3413I11
BCP31134
embelic acid; emberine; nsc 91874; nsc91874; nsc 91874
embelic acid;2,5-dihydroxy-3-undecyl-1,4-benzoquinone
AS-55903
BP-25395
AC-34763

Research Excerpts

Overview

ExcerptReference
"Embelin is a natural benzoquinone compound that displays a beneficial effect in various inflammatory-related diseases. "( Bai, X; Ding, S; Guo, S; Jiang, M; Mu, W; Pei, B; Wang, J; Yang, S; Yao, M; Zhang, M; Zhu, X, 2023)
"Embelin is an active component isolated from Embelia ribes Burm. "( Wang, D; Wang, H; Wang, Y; Yang, L; Zhang, H, 2019)
"Embelin is a naturally occurring para-benzoquinone isolated from Embelia ribes (Burm. "( Chen, WH; Chen, X; Gao, M; Ge, S; Jian, R; Li, D; Sheng, Z; Xu, X; Zhang, K, 2020)
"Embelin is an active ingredient of traditional herbal remedies for cancer and other diseases. "( Kang, HM; Kim, IR; Lee, YJ; Park, BS; Park, HR; Yu, SB, 2017)
"Embelin is a phytochemical component of tropical plants that have a long history of being used in ethnic pharmacology in various parts of the world, including Ayurdvedic and Chinese medicinal texts. "( Caruso, F; Paumier, S; Rossi, M, 2018)
"Embelin is a naturally-occurring benzoquinone compound that has been shown to possess many biological properties relevant to human cancer prevention and treatment, and increasing evidence indicates that embelin may modulate various characteristic hallmarks of tumor cells. "( Ahn, KS; Ko, JH; Lee, SG; Mishra, S; Sethi, G; Shanmugam, MK; Um, JY; Yang, WM, 2018)
"Embelin is a natural compound possessing a plethora of pharmacological activities, including antidiabetic activity. "( Abidin, L; Ahad, A; Alam, MS; Aqil, M; Mir, SR; Mujeeb, M, 2018)
"Embelin is an active compound identified as a novel X-linked inhibitor of apoptosis protein (XIAP) inhibitor from the Embelia ribes that exhibits various medicinal effects including anti-inflammatory and anticancer activities. "( Chen, Y; Cheng, S; Gong, W; Huang, T; Jiang, G; Li, P; Li, X; Qian, H; Zhang, W, 2018)
"Embelin is an active compound identified as a novel XIAP inhibitor from the Embelia ribes that exhibits various medicinal effects including anti-inflammatory and anti-cancer activities."( Ahn, KS; Jang, HJ; Kim, SH; Lee, JH; Lee, SG; Lim, SL; Park, SY; Um, JY, 2013)
"Embelin is a benzoquinone phytochemical isolated from the Japanese herb Ardisiae Japonicae and has been shown to induce apoptosis in cancer cells."( Edderkaoui, M; Eibl, G; Go, VL; Hui, H; Li, G; Lu, QY; Lu, X; Lugea, A; Moro, A; Pandol, SJ, 2013)
"Embelin acts as an NF-κB blocker and potential suppressor of tumorigenesis."( Poojari, R, 2014)
"Embelin is a small molecule inhibitor of X-linked inhibitor of apoptosis protein (XIAP), with antioxidant, anti-inflammatory, and antitumor activities."( Dai, Y; George, J; Hebbard, L; Jiao, H; Qiao, L; Teng, G; Wang, W; Wang, Y; Zhang, R, 2014)
"Embelin is a potent XIAP inhibitor which has been shown to inhibit the proliferation of tumor cells and cause cell apoptosis."( Chen, X; Huang, Q; Jin, T; Lan, J; Liu, X; Mou, X; Sun, X; Wang, S; Yang, P; Yang, T, 2015)
"Embelin is an active compound identified as a novel X-chromosome-linked IAP (XIAP) inhibitor from the Embelia ribes that exhibits various medicinal effects including anti-inflammatory and anti-cancer activities."( Chen, S; Fu, X; Li, Y; Pang, X; Qi, H; Tan, W, 2016)
"Embelin (EB) is a benzoquinone derivative isolated from Embelia ribes Burm plant. "( Ahn, KS; Baek, SH; Kim, SH; Ko, JH; Lee, H; Lee, J; Lee, SG; Nam, D; Shim, BS; Um, JY; Yang, WM, 2016)
"Embelin is a small-molecule inhibitor of X‑linked inhibitor of apoptosis protein (XIAP), and it induces apoptosis in tumor cells via the inhibition of XIAP. "( Pei, JH; Shen, SJ; Wang, JZ; Xu, CL; Zheng, B, 2016)
"Embelin is an active component extracted from the fruits of Embelia ribes."( Lu, H; Qiao, L; Wang, J; Wang, Y; Zhou, Y, 2016)
"Embelin is a potent dual inhibitor of 5-lipoxigenase (5-LOX) and microsomal prostaglandin E2 synthase (mPGES)-1 that suppresses proliferation of human glioma cells and induces apoptosis by inhibiting XIAP and NF-κB signaling pathway. "( Caraglia, M; Cossu, AM; De Rosa, M; Filosa, R; Ingrosso, D; Schiraldi, C; Scuotto, M; Zappavigna, S, 2016)
"Embelin is a natural product and exhibits antitumor activity through blocking the activity of X-linked inhibitor of apoptosis protein (XIAP)."( Gao, X; Huang, Y; Li, J; Li, S; Lu, J; Marquez, RT; Meng, X; Venkataramanan, R; Wang, Z; Zhao, W, 2013)
"Embelin is a natural product, inhibitor of XIAP (X-chromosome-linked Inhibitor of APoptosis) with strong proapoptotic properties on cancer cells. "( Babu, KS; Barillé-Nion, S; Gautier, F; Grée, R; Juin, P; Tasseau, O; Viault, G, 2013)

Effects

ExcerptReference
"Embelin treatment has significantly protected synaptic plasticity impairment as assessed by hippocampal long-term potentiation (LTP) test."( Bakar, SNS; Bhuvanendran, S; Hassan, Z; Kumari, Y; Othman, I; Shaikh, MF, 2019)
"Embelin has the anti-inflammatory property."( Gowthami, M; Honeyshmitha, D; Krishna, CG; Manasa, J; Meghana, K; Qin, X; Sita, GJA; Sowjanya, NL; SreeHarsha, N; Srikanth, G; Sushma, KR, 2019)
"Embelin has become known specifically for its antihelminthic and contraceptive use."( Poojari, R, 2014)
"Embelin has been used to treat fever and inflammatory diseases for thousands of years. "( Li, JG; Tang, ZZ; Zhang, WK; Zhao, ZG, 2015)
"Embelin has the ability to enhance TRAIL-induced apoptosis and activate caspase pathway."( Chen, X; Huang, Q; Jin, T; Lan, J; Liu, X; Mou, X; Sun, X; Wang, S; Yang, P; Yang, T, 2015)
"Embelin has been reported to suppress cytokine expressions in inflammatory disorders."( Cao, J; Huang, L; Zhou, XL, 2015)
"Embelin has been reported to possess antiinflammatory, neuroprotective and anxiolytic assets and has been shown to inhibit nuclear factor κB pathway and cytokine production."( Badami, S; Dhadde, SB; Durg, S; Patil, JS; Shaikh, A; Thippeswamy, BS; Veerapur, VP, 2016)
"Embelin has the potential to prevent body weight gain and fat accumulation, and to improve obesity-related glucose tolerance impairment and insulin resistance in the HFD-fed mice."( Gao, Y; Li, J; Li, X; Wang, B; Wang, S; Xu, X; Yang, Y; Zhang, L; Zheng, F; Zhou, J, 2017)
"Embelin has been reported to exhibit therapeutic activity in cancer. "( Gaiser, T; Siegelin, MD; Siegelin, Y, 2009)
"Embelin has been used to treat fever, inflammatory diseases, and a variety of gastrointestinal ailments for thousands of years. "( Honnegowda, S; Kulkarni, NM; Kumar G, K, 2011)

Actions

ExcerptReference
"Embelin could enhance TRAIL-induced apoptosis in A549 cells. "( Hao, JL; Jiang, L; Jin, ML; Wei, P; Zhang, YG, 2013)

Treatment

ExcerptReference
"The embelin treatment significantly increased the glucose levels and lactate dehydrogenase B (LDHB) activity in sows plasma, and decreased the lactate levels in both sows and fetuses plasma (P < 0.05)."( Bao, Z; Huang, F; Liu, X; Lv, C; Wang, T; Yao, W, 2023)
"Embelin treatment caused inhibitory effects on the IL-1β-stimulated production of COX-2, IL-6, IL-8, and TNF-α, which were abolished by LY294002 treatment."( Bai, X; Ding, S; Guo, S; Jiang, M; Mu, W; Pei, B; Wang, J; Yang, S; Yao, M; Zhang, M; Zhu, X, 2023)
"Embelin treatment has significantly protected synaptic plasticity impairment as assessed by hippocampal long-term potentiation (LTP) test."( Bakar, SNS; Bhuvanendran, S; Hassan, Z; Kumari, Y; Othman, I; Shaikh, MF, 2019)
"Embelin treatment significantly decreased MDA and increased SOD, CAT, and GSH Px."( SreeHarsha, N, 2020)
"Embelin (EMB) treatment increased the seizure threshold to hind limb extension (HLE) in the ICES test and decreased the seizure scores in the kindling experiment. "( Agarwal, NB; Hoda, U; Jain, GK; Jain, S; Samim, M, 2021)
"Embelin pre-treatment significantly inhibited apomorphine-induced climbing and stereotyped behaviours in mice and rats, respectively. "( B, NK; Badami, S; Dhadde, SB; Durg, S; Thippeswamy, BS; Vandal, R; Veerapur, VP, 2017)
"Embelin treatment demonstrated a significant curtailment of oxidative stress as well as increased the activities of antioxidant enzymes, endogenously."( Gowthami, M; Honeyshmitha, D; Krishna, CG; Manasa, J; Meghana, K; Qin, X; Sita, GJA; Sowjanya, NL; SreeHarsha, N; Srikanth, G; Sushma, KR, 2019)
"Embelin treatment to HFD+STZ diabetic rats also improved the altered histoarchitecture of β-islets of pancreas and hepatocytes."( Ansari, AA; Naik, SR; Niture, NT; Shah, PD, 2013)
"Embelin treatment resulted in decreased XIAP protein levels by 8 hours of treatment with maximal effect at 16 hours in KMCH and Mz-ChA-1 cells."( Gutwein, AR; Mott, JL; Natarajan, SK; Phillippi, MA; Wehrkamp, CJ, 2014)
"Embelin-treated mice showed significant inhibition in tumor growth which was associated with reduced expression of markers of cell proliferation (Ki67, PCNA and Bcl-2) and cell cycle (cyclin D1, CDK2, and CDK6), and induction of apoptosis (activation of caspase-3 and cleavage of PARP, and increased expression of Bax)."( Huang, M; Jackman, CP; Marsh, JL; Shankar, S; Srivastava, RK; Tang, SN; Upadhyay, G, 2014)
"Embelin treatment caused growth inhibition and apoptosis in PTC cell lines and induced tumor regression in PTC xenograft in nude mice."( Ahmed, M; Al-Dayel, F; Al-Kuraya, KS; Al-Sobhi, S; Beg, S; Bu, R; Hussain, AR; Jehan, Z; Siraj, AK; Uddin, S, 2015)
"Embelin treatment suppressed ST2 and C3H10T1/2 cells to proliferate, and differentiate into mature adipocytes, along with the inhibition of adipogenic factors peroxisome proliferator-activated receptor γ, CCAAT/enhancer binding protein-α, adipocyte protein 2 and adipsin. "( Gao, Y; Li, J; Li, X; Wang, B; Wang, S; Xu, X; Yang, Y; Zhang, L; Zheng, F; Zhou, J, 2017)
"Embelin treatment significantly prevented NDEA or CCl4 induced increase in biochemical marker enzymes: glutamate pyruvate transaminase, glutamate oxaloacetate transaminase, alkaline phosphatase, gamma-glutamyl transpeptidase, glutathione-S-transferase, lipid peroxidase as well as hypoproteinemia, hypoalbuminuria and glutathione depletion."( Bhagwat, S; Gupta, S; Khade, B; Maru, G; Poojari, R, 2010)
"Embelin treatment significantly decreased clinical activity score, gross lesion score, percent affected area and wet colon weight when compared to acetic acid induced controls."( Badami, S; Biradar, MI; Mahendran, S; Raj, P; Srivastava, K; Thippeswamy, BS; Veerapur, VP, 2011)
"Embelin treatment significantly exacerbated stroke-induced injury in females but had no effect in males, demonstrating that XIAP is an important mediator of sex-specific responses after stroke."( Benashski, SE; Li, J; Liu, F; McCullough, LD; Siegel, C, 2011)
"Embelin treatment also lowered the serum levels of glucose by 24.77 %, insulin by 35.03 %, and leptin by 43.39 %."( Bhandari, U; Chaudhari, HS; Khanna, G, 2012)
"Embelin treatment resulted in activation of extracellular signal-regulated kinase (ERK)1/2 and ROS accumulation, which correlated with downregulation of antioxidant protein SOD1 and consumption of redox modulator reduced glutathione in the XIAP-overexpressing cells."( Aird, KM; Aldrich, AJ; Allensworth, JL; Batinic-Haberle, I; Devi, GR, 2012)
"In embelin treated groups (4 mg/ml of 0.2% sodium alginate gel), epithelialization of the incision wound was faster with a high rate of wound contraction."( Abdul Rahiman, B; Harish, BG; Krishna, V; Kumara Swamy, HM; Mahadevan, KM; Mankani, KL; Raja Naika, H; Shankarmurthy, K, 2007)
"Embelin treatment also caused a significant increase in the microsomal glucose-6-phosphatase and the cytosolic enzyme, lactate dehydrogenase."( Gupta, S; Kanwar, U; Sanyal, SN, 1990)
"Treatment with embelin at the doses of 0.3 and 0.6 mg/kg significantly reversed the spatial memory impairment induced by CCH in rats."( Bakar, SNS; Bhuvanendran, S; Hassan, Z; Kumari, Y; Othman, I; Shaikh, MF, 2019)
"Treatment with embelin (25 and 50 mg/kg) upgrades the function of kidneys, by elevating antioxidant levels and reducing the MDA level in cisplatin-administered rats."( Gowthami, M; Honeyshmitha, D; Krishna, CG; Manasa, J; Meghana, K; Qin, X; Sita, GJA; Sowjanya, NL; SreeHarsha, N; Srikanth, G; Sushma, KR, 2019)
"Treatment of embelin (25 and 50 mg/kg/day, p.o.) for 3 weeks to HFD+STZ diabetic rats elicited insignificant increase in body weight, reduced the elevated plasma glucose, glycosylated haemoglobin and pro-inflammatory mediators (interleukin 6 and tumour necrosis factor α) significantly."( Ansari, AA; Naik, SR; Niture, NT; Shah, PD, 2013)
"Pretreatment with embelin (5, 10 and 20 mg/kg, i.p.) decreased lung edema, mononucleated cellular infiltration, nitrate/nitrite, total protein, albumin concentrations, TNF-α in the bronchoalveolar lavage fluid and myeloperoxidase activity in lung homogenate. "( Saraf, MN; Shirole, NL; Shirole, RL, 2015)
"Treatment with embelin LNs decreased MPO, LDH and LPO levels, increased reduced GSH levels which indicated better treatment of ulcerative colitis was achieved."( Badamaranahalli, SS; Bhagawati, ST; Durg, S; Kopparam, M, 2015)
"Pre-treatment with embelin attenuated behavioural changes induced by LPS."( Badami, S; Dhadde, SB; Durg, S; Patil, JS; Shaikh, A; Thippeswamy, BS; Veerapur, VP, 2016)
"Pretreatment of embelin (25 and 50 mg/kg, p.o.) significantly increased locomotor activity and hanging latency time and decreased beam walking latency when compared with ischemic control."( Badami, S; Mahendran, S; Nagakannan, P; Shivasharan, BD; Thippeswamy, BS; Veerapur, VP, 2011)

Roles (4)

RoleDescription
hepatitis C protease inhibitorAn inhibitor of hepatitis C protease, an enzyme required for production of proteins needed for viral assembly.
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
dihydroxy-1,4-benzoquinonesA hydroxybenzoquinone that is any 1,4-benzoquinone in which two of the substituents on the quinone ring are hydroxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (58)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency35.48130.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency5.01190.004023.8416100.0000AID485290
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency25.05940.140911.194039.8107AID2451
Chain A, HADH2 proteinHomo sapiens (human)Potency21.48650.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency21.48650.025120.237639.8107AID886; AID893
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency33.99720.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency12.20970.177814.390939.8107AID2147
ClpPBacillus subtilisPotency10.00001.995322.673039.8107AID651965
15-lipoxygenase, partialHomo sapiens (human)Potency5.01190.012610.691788.5700AID887
USP1 protein, partialHomo sapiens (human)Potency35.48130.031637.5844354.8130AID743255
GLS proteinHomo sapiens (human)Potency17.78280.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency23.72460.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency29.08390.180013.557439.8107AID1460; AID1468
Smad3Homo sapiens (human)Potency19.95260.00527.809829.0929AID588855
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency39.81070.707912.194339.8107AID720542
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency27.83970.011212.4002100.0000AID1030
EWS/FLI fusion proteinHomo sapiens (human)Potency29.94390.001310.157742.8575AID1259252; AID1259253; AID1259256
GVesicular stomatitis virusPotency30.11160.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency6.74120.00108.379861.1304AID1645840
67.9K proteinVaccinia virusPotency12.35640.00018.4406100.0000AID720579; AID720580
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency16.80910.00207.533739.8107AID891
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency12.58930.316212.443531.6228AID902; AID924
polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)Potency8.91251.000012.232631.6228AID1452
cytochrome P450 2C19 precursorHomo sapiens (human)Potency39.81070.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency25.11890.00636.904339.8107AID883
D(2) dopamine receptor isoform longHomo sapiens (human)Potency22.28030.04580.04580.0458AID624453
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency19.62210.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency46.14370.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency26.63210.006026.168889.1251AID540317
importin subunit beta-1 isoform 1Homo sapiens (human)Potency125.89205.804836.130665.1308AID540263
mitogen-activated protein kinase 1Homo sapiens (human)Potency0.12590.039816.784239.8107AID1454
flap endonuclease 1Homo sapiens (human)Potency17.78280.133725.412989.1251AID588795
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency3.16230.65619.452025.1189AID927
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency29.93490.168316.404067.0158AID720504
snurportin-1Homo sapiens (human)Potency125.89205.804836.130665.1308AID540263
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency28.18380.425612.059128.1838AID504891
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.71640.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency0.10320.004611.374133.4983AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency20.26770.031622.3146100.0000AID588579
lethal factor (plasmid)Bacillus anthracis str. A2012Potency7.55060.020010.786931.6228AID912
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency31.62280.316212.765731.6228AID881
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency84.21816.309660.2008112.2020AID720707; AID720709
Interferon betaHomo sapiens (human)Potency30.11160.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency30.11160.01238.964839.8107AID1645842
Integrin beta-3Homo sapiens (human)Potency12.58930.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency12.58930.316211.415731.6228AID924
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency27.72050.00638.235039.8107AID881; AID883
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)Potency3.16231.584913.004325.1189AID927
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency1.58491.000010.475628.1838AID1457
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency30.11160.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency30.11160.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Prostaglandin E synthaseHomo sapiens (human)IC50 (µMol)0.20000.00102.030810.0000AID1357415
Polyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)IC50 (µMol)1.22400.00011.68479.3200AID1201305; AID1201306; AID1201309; AID1201310; AID1201312
E3 ubiquitin-protein ligase XIAPHomo sapiens (human)IC50 (µMol)4.10000.00750.62274.1000AID1447411; AID41545; AID41547
E3 ubiquitin-protein ligase XIAPHomo sapiens (human)Ki0.40000.00200.10670.4000AID276477
Macrophage-expressed gene 1 proteinHomo sapiens (human)IC50 (µMol)0.21000.21002.52409.1000AID1201316; AID1201318
Histone acetyltransferase KAT2BHomo sapiens (human)IC50 (µMol)7.20005.00006.01678.5000AID1282390
G-protein coupled receptor 84Homo sapiens (human)Ki0.02360.02361.29013.3100AID1546369
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
streptokinase A precursorStreptococcus pyogenes M1 GASEC50 (µMol)1.67100.06008.9128130.5170AID1902
G-protein coupled receptor 84Homo sapiens (human)EC50 (µMol)2.08860.08903.868710.0000AID1447407; AID1447408; AID1447441; AID1447442; AID1546374; AID1546376; AID1546379; AID1546380; AID1546381; AID1546382
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (283)

Processvia Protein(s)Taxonomy
prostaglandin biosynthetic processProstaglandin E synthaseHomo sapiens (human)
prostaglandin metabolic processProstaglandin E synthaseHomo sapiens (human)
signal transductionProstaglandin E synthaseHomo sapiens (human)
cell population proliferationProstaglandin E synthaseHomo sapiens (human)
negative regulation of cell population proliferationProstaglandin E synthaseHomo sapiens (human)
sensory perception of painProstaglandin E synthaseHomo sapiens (human)
regulation of fever generationProstaglandin E synthaseHomo sapiens (human)
positive regulation of prostaglandin secretionProstaglandin E synthaseHomo sapiens (human)
regulation of inflammatory responseProstaglandin E synthaseHomo sapiens (human)
cellular oxidant detoxificationProstaglandin E synthaseHomo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
negative regulation of endothelial cell proliferationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte chemotaxis involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte migration involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
humoral immune responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of bone mineralizationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
dendritic cell migrationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
glucose homeostasisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
long-chain fatty acid biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of fat cell differentiationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of insulin secretionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of vascular wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory response to woundingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cytokine production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cellular response to oxidative stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene A4 biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of response to endoplasmic reticulum stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of sprouting angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cellPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxin biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to hypoxiaDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
neutrophil mediated immunityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
germinal center formationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of leukocyte chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch receptor processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell population proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to xenobiotic stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of T cell chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
signal releaseDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
B cell differentiationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell growthDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to lipopolysaccharideDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of chemokine productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
regulation of mast cell apoptotic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
T cell differentiation in thymusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
wound healing, spreading of epidermal cellsDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
spleen developmentDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell motilityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
defense response to Gram-positive bacteriumDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cellular response to high density lipoprotein particle stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
commissural neuron axon guidanceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of cold-induced thermogenesisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
regulation of apoptotic processE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
DNA damage responseE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
negative regulation of tumor necrosis factor-mediated signaling pathwayE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
Wnt signaling pathwayE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
regulation of BMP signaling pathwayE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
positive regulation of protein ubiquitinationE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
positive regulation of type I interferon productionE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
regulation of cell population proliferationE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
defense response to bacteriumE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
negative regulation of apoptotic processE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
regulation of innate immune responseE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
positive regulation of JNK cascadeE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
regulation of inflammatory responseE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
neuron apoptotic processE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
copper ion homeostasisE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
regulation of apoptosis involved in tissue homeostasisE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
regulation of nucleotide-binding domain, leucine rich repeat containing receptor signaling pathwayE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
nucleotide-binding oligomerization domain containing 1 signaling pathwayE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathwayE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
protein K63-linked ubiquitinationE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
inhibition of cysteine-type endopeptidase activityE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
positive regulation of protein linear polyubiquitinationE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
regulation of cell cycleE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
adaptive immune responseMacrophage-expressed gene 1 proteinHomo sapiens (human)
dendritic cell antigen processing and presentationMacrophage-expressed gene 1 proteinHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigenMacrophage-expressed gene 1 proteinHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IMacrophage-expressed gene 1 proteinHomo sapiens (human)
defense response to bacteriumMacrophage-expressed gene 1 proteinHomo sapiens (human)
defense response to Gram-negative bacteriumMacrophage-expressed gene 1 proteinHomo sapiens (human)
defense response to Gram-positive bacteriumMacrophage-expressed gene 1 proteinHomo sapiens (human)
transmembrane transportMacrophage-expressed gene 1 proteinHomo sapiens (human)
antibacterial innate immune responseMacrophage-expressed gene 1 proteinHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone acetyltransferase KAT2BHomo sapiens (human)
positive regulation of transcription from RNA polymerase II promoter by glucoseHistone acetyltransferase KAT2BHomo sapiens (human)
gluconeogenesisHistone acetyltransferase KAT2BHomo sapiens (human)
regulation of DNA repairHistone acetyltransferase KAT2BHomo sapiens (human)
chromatin remodelingHistone acetyltransferase KAT2BHomo sapiens (human)
regulation of DNA-templated transcriptionHistone acetyltransferase KAT2BHomo sapiens (human)
regulation of transcription by RNA polymerase IIHistone acetyltransferase KAT2BHomo sapiens (human)
protein acetylationHistone acetyltransferase KAT2BHomo sapiens (human)
heart developmentHistone acetyltransferase KAT2BHomo sapiens (human)
memoryHistone acetyltransferase KAT2BHomo sapiens (human)
negative regulation of cell population proliferationHistone acetyltransferase KAT2BHomo sapiens (human)
regulation of protein ADP-ribosylationHistone acetyltransferase KAT2BHomo sapiens (human)
positive regulation of neuron projection developmentHistone acetyltransferase KAT2BHomo sapiens (human)
N-terminal peptidyl-lysine acetylationHistone acetyltransferase KAT2BHomo sapiens (human)
internal peptidyl-lysine acetylationHistone acetyltransferase KAT2BHomo sapiens (human)
peptidyl-lysine acetylationHistone acetyltransferase KAT2BHomo sapiens (human)
cellular response to insulin stimulusHistone acetyltransferase KAT2BHomo sapiens (human)
cellular response to oxidative stressHistone acetyltransferase KAT2BHomo sapiens (human)
vasodilationHistone acetyltransferase KAT2BHomo sapiens (human)
regulation of RNA splicingHistone acetyltransferase KAT2BHomo sapiens (human)
positive regulation of gluconeogenesisHistone acetyltransferase KAT2BHomo sapiens (human)
positive regulation of fatty acid biosynthetic processHistone acetyltransferase KAT2BHomo sapiens (human)
transcription initiation-coupled chromatin remodelingHistone acetyltransferase KAT2BHomo sapiens (human)
positive regulation of glycolytic processHistone acetyltransferase KAT2BHomo sapiens (human)
positive regulation of DNA-templated transcriptionHistone acetyltransferase KAT2BHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone acetyltransferase KAT2BHomo sapiens (human)
regulation of embryonic developmentHistone acetyltransferase KAT2BHomo sapiens (human)
negative regulation of centriole replicationHistone acetyltransferase KAT2BHomo sapiens (human)
rhythmic processHistone acetyltransferase KAT2BHomo sapiens (human)
regulation of cell divisionHistone acetyltransferase KAT2BHomo sapiens (human)
regulation of cell cycleHistone acetyltransferase KAT2BHomo sapiens (human)
limb developmentHistone acetyltransferase KAT2BHomo sapiens (human)
cellular response to parathyroid hormone stimulusHistone acetyltransferase KAT2BHomo sapiens (human)
regulation of tubulin deacetylationHistone acetyltransferase KAT2BHomo sapiens (human)
positive regulation of attachment of mitotic spindle microtubules to kinetochoreHistone acetyltransferase KAT2BHomo sapiens (human)
negative regulation of rRNA processingHistone acetyltransferase KAT2BHomo sapiens (human)
biological_processG-protein coupled receptor 84Homo sapiens (human)
neuropeptide signaling pathwayG-protein coupled receptor 84Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (91)

Processvia Protein(s)Taxonomy
glutathione transferase activityProstaglandin E synthaseHomo sapiens (human)
glutathione peroxidase activityProstaglandin E synthaseHomo sapiens (human)
prostaglandin-D synthase activityProstaglandin E synthaseHomo sapiens (human)
protein bindingProstaglandin E synthaseHomo sapiens (human)
glutathione bindingProstaglandin E synthaseHomo sapiens (human)
prostaglandin-E synthase activityProstaglandin E synthaseHomo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
arachidonate 5-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
iron ion bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
protein bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
hydrolase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
endopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
interleukin-6 receptor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
peptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytokine bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
PDZ domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
tumor necrosis factor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
ubiquitin-protein transferase activityE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
cysteine-type endopeptidase inhibitor activityE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
protein bindingE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
identical protein bindingE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
metal ion bindingE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
endopeptidase regulator activityE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
ubiquitin protein ligase activityE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
protein serine/threonine kinase bindingE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
wide pore channel activityMacrophage-expressed gene 1 proteinHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingHistone acetyltransferase KAT2BHomo sapiens (human)
chromatin bindingHistone acetyltransferase KAT2BHomo sapiens (human)
transcription coregulator activityHistone acetyltransferase KAT2BHomo sapiens (human)
transcription coactivator activityHistone acetyltransferase KAT2BHomo sapiens (human)
diamine N-acetyltransferase activityHistone acetyltransferase KAT2BHomo sapiens (human)
histone acetyltransferase activityHistone acetyltransferase KAT2BHomo sapiens (human)
lysine N-acetyltransferase activity, acting on acetyl phosphate as donorHistone acetyltransferase KAT2BHomo sapiens (human)
cyclin-dependent protein serine/threonine kinase inhibitor activityHistone acetyltransferase KAT2BHomo sapiens (human)
protein bindingHistone acetyltransferase KAT2BHomo sapiens (human)
acetyltransferase activityHistone acetyltransferase KAT2BHomo sapiens (human)
protein kinase bindingHistone acetyltransferase KAT2BHomo sapiens (human)
histone acetyltransferase bindingHistone acetyltransferase KAT2BHomo sapiens (human)
histone deacetylase bindingHistone acetyltransferase KAT2BHomo sapiens (human)
histone H3K9 acetyltransferase activityHistone acetyltransferase KAT2BHomo sapiens (human)
peptide-lysine-N-acetyltransferase activityHistone acetyltransferase KAT2BHomo sapiens (human)
DNA-binding transcription factor bindingHistone acetyltransferase KAT2BHomo sapiens (human)
histone H3 acetyltransferase activityHistone acetyltransferase KAT2BHomo sapiens (human)
urotensin II receptor activityG-protein coupled receptor 84Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (77)

Processvia Protein(s)Taxonomy
nuclear envelope lumenProstaglandin E synthaseHomo sapiens (human)
endoplasmic reticulum membraneProstaglandin E synthaseHomo sapiens (human)
membraneProstaglandin E synthaseHomo sapiens (human)
perinuclear region of cytoplasmProstaglandin E synthaseHomo sapiens (human)
membraneProstaglandin E synthaseHomo sapiens (human)
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular regionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
extracellular spacePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelope lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nucleoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
cytosolPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear matrixPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear membranePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
secretory granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
perinuclear region of cytoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
ficolin-1-rich granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
cell-cell junctionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
ruffle membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Golgi membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
endoplasmic reticulum lumenDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytosolDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
actin cytoskeletonDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
apical plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane raftDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
nucleusE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
nucleoplasmE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
cytoplasmE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
cytosolE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
nucleusE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
phagocytic vesicle membraneMacrophage-expressed gene 1 proteinHomo sapiens (human)
phagolysosome membraneMacrophage-expressed gene 1 proteinHomo sapiens (human)
extracellular regionMacrophage-expressed gene 1 proteinHomo sapiens (human)
cytoplasmic vesicleMacrophage-expressed gene 1 proteinHomo sapiens (human)
phagocytic vesicleMacrophage-expressed gene 1 proteinHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
SAGA complexHistone acetyltransferase KAT2BHomo sapiens (human)
kinetochoreHistone acetyltransferase KAT2BHomo sapiens (human)
nucleusHistone acetyltransferase KAT2BHomo sapiens (human)
nucleoplasmHistone acetyltransferase KAT2BHomo sapiens (human)
centrosomeHistone acetyltransferase KAT2BHomo sapiens (human)
cytosolHistone acetyltransferase KAT2BHomo sapiens (human)
A bandHistone acetyltransferase KAT2BHomo sapiens (human)
I bandHistone acetyltransferase KAT2BHomo sapiens (human)
actomyosinHistone acetyltransferase KAT2BHomo sapiens (human)
mitotic spindleHistone acetyltransferase KAT2BHomo sapiens (human)
ATAC complexHistone acetyltransferase KAT2BHomo sapiens (human)
protein-containing complexHistone acetyltransferase KAT2BHomo sapiens (human)
plasma membraneG-protein coupled receptor 84Homo sapiens (human)
specific granule membraneG-protein coupled receptor 84Homo sapiens (human)
tertiary granule membraneG-protein coupled receptor 84Homo sapiens (human)
receptor complexG-protein coupled receptor 84Homo sapiens (human)
plasma membraneG-protein coupled receptor 84Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (150)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1201317Inhibition of 15-LOX-1 in human blood PMNL assessed as remaining activity by measuring 15-HETE synthesis at 10 uM2015European journal of medicinal chemistry, Apr-13, Volume: 94Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1193496Thermodynamic equilibrium solubility, log S of the compound in water at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1091094Termiticidal activity against Coptotermes formosanus placed on 1 % wt/wt compound treated filter paper assessed as termite mortality measured 21 days post compound exposure2008Journal of agricultural and food chemistry, Jun-11, Volume: 56, Issue:11
Activity of 1,4-benzoquinones against formosan subterranean termites (Coptotermes formosanus).
AID1634710Antibacterial activity against Pseudomonas aeruginosa assessed as bacterial growth inhibition after 24 hrs by broth dilution method2016Journal of natural products, Apr-22, Volume: 79, Issue:4
Domino Synthesis of Embelin Derivatives with Antibacterial Activity.
AID1201318Inhibition of human mPGES12015European journal of medicinal chemistry, Apr-13, Volume: 94Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes.
AID156313Percent of PC-3 cells stained for activated caspase-9 after incubation with 40 uM of compound for 42h2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database.
AID1201309Inhibition of human recombinant 5-LOX expressed in Escherichia coli BL21 incubated for 10 mins in presence of arachidonic acid by RP-HPLC based cell-free assay2015European journal of medicinal chemistry, Apr-13, Volume: 94Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes.
AID1193493Thermodynamic equilibrium solubility, log S of the compound in PBS at pH 7.4 at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1201307Potency index, ratio of IC50 for human 5-LOX by intact cell based assay to IC50 for human 5-LOX by cell free assay2015European journal of medicinal chemistry, Apr-13, Volume: 94Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes.
AID1193499Thermodynamic equilibrium solubility, log S of the compound simulated intestinal fluid at pH 6.8 at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1193497Thermodynamic equilibrium solubility, log S of the compound PBS at pH 7.4 at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1282389Inhibition of full length recombinant His6-tagged p300 (unknown origin) expressed in baculovirus expression system using histone substrate at 25 uM after 10 mins by liquid scintillation counting method in presence of [3H]acetyl-CoA relative to control2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
KATching-Up on Small Molecule Modulators of Lysine Acetyltransferases.
AID1193495Thermodynamic equilibrium solubility, log S of the compound in simulated intestinal fluid at pH 6.8 at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID156185Activation of caspase-9 by embelin in PC-3 prostate cancer cells at a concentration of 40 uM2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database.
AID1282390Inhibition of full length recombinant FLAG-tagged PCAF (unknown origin) expressed in baculovirus expression system using histone substrate after 10 mins by liquid scintillation counting method in presence of [3H]acetyl-CoA2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
KATching-Up on Small Molecule Modulators of Lysine Acetyltransferases.
AID1193492Thermodynamic equilibrium solubility, log S of the compound in water at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1847369Inhibition of NDM-1 (unknown origin) using meropenem as substrate incubated for 10 mins2021European journal of medicinal chemistry, Nov-05, Volume: 223Recent research and development of NDM-1 inhibitors.
AID95461Inhibitory concentration of compound against Jurkat-Vec cells2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database.
AID156186Induction of apoptosis by embelin in PC-3 prostate cancer cells at a concentration of 25 uM for 48 h2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database.
AID95300Induction of apoptosis by etoposide in Jurkat vec cells at a dose of 2.5 uM for 72 h2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database.
AID1667757Inhibition of SET7 (unknown origin) using biotinylated histone polypeptide as substrate at 100 uM in presence of SAM by AlphaLISA assay relative to control2020Bioorganic & medicinal chemistry letters, 05-01, Volume: 30, Issue:9
Lead discovery, chemical optimization, and biological evaluation studies of novel histone methyltransferase SET7 small-molecule inhibitors.
AID102017Compound was tested for inhibition of LnCap prostate cancer cells2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database.
AID379518Cytotoxicity against human Bel-7402 cells after 96 hrs by MTT assay2006Journal of natural products, Nov, Volume: 69, Issue:11
A nitrogen-containing 3-alkyl-1,4-benzoquinone and a gomphilactone derivative from Embelia ribes.
AID379516Cytotoxicity against human A549 cells after 96 hrs by MTT assay2006Journal of natural products, Nov, Volume: 69, Issue:11
A nitrogen-containing 3-alkyl-1,4-benzoquinone and a gomphilactone derivative from Embelia ribes.
AID1546381Agonist activity at recombinant human GPR84 expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation by fluo-4AM dye based FLIPR assay2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID1357415Inhibition of mPGES1 in human A549 cell microsomes2018European journal of medicinal chemistry, Jun-10, Volume: 153Plant-derived mPGES-1 inhibitors or suppressors: A new emerging trend in the search for small molecules to combat inflammation.
AID1634707Antibacterial activity against vancomycin/methicillin-sensitive Staphylococcus aureus ATCC 25923 assessed as bacterial growth inhibition after 24 hrs by broth dilution method2016Journal of natural products, Apr-22, Volume: 79, Issue:4
Domino Synthesis of Embelin Derivatives with Antibacterial Activity.
AID1201319Inhibition of 12-LOX in human blood PMNL assessed as remaining activity by measuring 12-HETE synthesis at 10 uM2015European journal of medicinal chemistry, Apr-13, Volume: 94Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes.
AID1546369Displacement of [3H]PSB-1584 from recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 measured after 6 hrs by scintillation counting method2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID1091127Antifeedant activity against Coptotermes formosanus placed on 1 % wt/wt compound treated filter paper assessed as filter paper consumption measured 21 days post compound exposure (Rvb = 85 +/- 15.1 mg)2008Journal of agricultural and food chemistry, Jun-11, Volume: 56, Issue:11
Activity of 1,4-benzoquinones against formosan subterranean termites (Coptotermes formosanus).
AID379517Cytotoxicity against human A2780 cells after 96 hrs by MTT assay2006Journal of natural products, Nov, Volume: 69, Issue:11
A nitrogen-containing 3-alkyl-1,4-benzoquinone and a gomphilactone derivative from Embelia ribes.
AID161358Selectivity in normal human prostate epithelial cells (PrEC)2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database.
AID1546394Selectivity ratio of EC50 for agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as inhibition of forskolin-stimulated [3H]cAMP accumulation to Ki for displacement of [3H]PSB-1584 from recombi2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID1201312Inhibition of 5-LOX in A23187-stimulated human blood PMNL assessed as reduction in lipoxygenase products formation in presence of arachidonic acid pre-incubated for 15 mins followed by stimulation with A23187 for 10 mins by RP-HPLC based cell based assay2015European journal of medicinal chemistry, Apr-13, Volume: 94Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes.
AID1847370Binding affinity to NDM-1 (unknown origin) assessed as inhibition constant using meropenem as substrate incubated for 10 mins2021European journal of medicinal chemistry, Nov-05, Volume: 223Recent research and development of NDM-1 inhibitors.
AID156021Percent of PC-3 cells underwent apoptosis after incubation with 50 uM of compound for 48 hr2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database.
AID158506Antimalarial activity against Plasmodium berghei.1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Structure-activity analyzed by pattern recognition: the asymmetric case.
AID1546379Agonist activity at recombinant human GPR84 expressed in HEK293 cells co-expressing Gqi5 assessed as inhibition of forskolin-induced cAMP accumulation by fluo-4AM dye based FLIPR assay2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID1447408Agonist activity at human GPR84 expressed in CHO cells assessed as beta-arrestin recruitment after 90 mins by beta-galactosidase complementation assay
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID41547Inhibitory concentration of compound against XIAP BIR3 protein2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database.
AID41545Compound was tested for inhibitory activity towards XIAP BIR3 protein2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database.
AID23447Partition coefficient (logP)1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Structure-activity analyzed by pattern recognition: the asymmetric case.
AID156187Induction of apoptosis by embelin in PC-3 prostate cancer cells at a concentration of 50 uM for 48 h2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database.
AID1091095Termiticidal activity against Coptotermes formosanus placed on 1 % wt/wt compound treated filter paper assessed as termite mortality measured 11 days post compound exposure2008Journal of agricultural and food chemistry, Jun-11, Volume: 56, Issue:11
Activity of 1,4-benzoquinones against formosan subterranean termites (Coptotermes formosanus).
AID1447407Agonist activity at Gi coupled human GPR84 expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation after 15 mins in presence of [3H]-cAMP by radiometric assay
AID1193500Thermodynamic equilibrium solubility, log S of the compound2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID379519Cytotoxicity against human BGC-823 cells after 96 hrs by MTT assay2006Journal of natural products, Nov, Volume: 69, Issue:11
A nitrogen-containing 3-alkyl-1,4-benzoquinone and a gomphilactone derivative from Embelia ribes.
AID1447441Agonist activity at human PK-tagged GPR84 expressed in CHOK1 cells assessed as EA-tagged beta-arrestin recruitment by beta-galactosidase complementation assay
AID218259Selectivity in normal human fibroblast cell line, WI-38 cells2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database.
AID1546382Agonist activity at recombinant human HA-tagged GPR84 stably expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation measured after 60 mins by HTRF assay2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID156312Percent of PC-3 cells stained for activated caspase-9 after incubation with 20 uM of compound for 42h2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database.
AID379521Inhibition of PTP1B at 50 uM2006Journal of natural products, Nov, Volume: 69, Issue:11
A nitrogen-containing 3-alkyl-1,4-benzoquinone and a gomphilactone derivative from Embelia ribes.
AID1193498Thermodynamic equilibrium solubility, log S of the compound simulated gastric fluid at pH 1.2 at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1634709Antibacterial activity against Escherichia coli assessed as bacterial growth inhibition after 24 hrs by broth dilution method2016Journal of natural products, Apr-22, Volume: 79, Issue:4
Domino Synthesis of Embelin Derivatives with Antibacterial Activity.
AID156175Inhibitory concentration of compound against growth of PC-3 cells in vitro2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database.
AID1546374Agonist activity at recombinant human N-terminal epitope tagged/C-terminal eYFP-fused FLAG-tagged GPR84 expressed in Flp-In TREx 293 cell membranes assessed as stimulation of [35S]GTPgammaS binding preincubated for 15 mins followed by [35S]GTPgammaS addit2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID218269Inhibitory concentration of compound against growth of WI-38 cells in vitro2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database.
AID1634708Antibacterial activity against vancomycin-intermediate/methicillin-resistant Staphylococcus aureus NRS402 assessed as bacterial growth inhibition after 24 hrs by broth dilution method2016Journal of natural products, Apr-22, Volume: 79, Issue:4
Domino Synthesis of Embelin Derivatives with Antibacterial Activity.
AID1282391Inhibition of TIP60 (unknown origin) expressed in bacterial system using histone substrate at 25 uM after 10 mins by liquid scintillation counting method in presence of [3H]acetyl-CoA relative to control2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
KATching-Up on Small Molecule Modulators of Lysine Acetyltransferases.
AID156160Compound was tested for inhibition of PC-3 prostate cancer cells2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database.
AID1866672Inhibition of yeast alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated with enzyme for 10 mins followed by substrate addition measured after 20 mins by spectrophotometric method2022Journal of natural products, 04-22, Volume: 85, Issue:4
α-Glucosidase Inhibitors from the Stems of
AID1201305Inhibition of human 5-LOX by cell free assay2015European journal of medicinal chemistry, Apr-13, Volume: 94Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes.
AID1091096Termiticidal activity against Coptotermes formosanus placed on 1 % wt/wt compound treated filter paper assessed as termite mortality measured 3 days post compound exposure2008Journal of agricultural and food chemistry, Jun-11, Volume: 56, Issue:11
Activity of 1,4-benzoquinones against formosan subterranean termites (Coptotermes formosanus).
AID1546380Agonist activity at recombinant human GPR84 expressed in CHO cells assessed as beta-arrestin 2 recruitment by beta-galactosidase based PathHunter assay2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID1193494Thermodynamic equilibrium solubility, log S of the compound in simulated gastric fluid at pH 1.2 at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1447406Agonist activity at Gi coupled human GPR84 expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation at 10 uM after 15 mins in presence of [3H]-cAMP by radiometric assay relative to decanoic acid
AID379520Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay2006Journal of natural products, Nov, Volume: 69, Issue:11
A nitrogen-containing 3-alkyl-1,4-benzoquinone and a gomphilactone derivative from Embelia ribes.
AID156184Activation of caspase-9 by embelin in PC-3 prostate cancer cells at a concentration of 20 uM2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database.
AID1546393Selectivity ratio of EC50 for agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as beta-arrestin 2 recruitment to Ki for displacement of [3H]PSB-1584 from recombinant human GPR84 expressed in2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID1447411Inhibition of XIAP (unknown origin)
AID161299Inhibitory concentration of compound against growth of PrEC cells in vitro2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database.
AID1201310Inhibition of 5-LOX in A23187-stimulated human blood PMNL assessed as reduction in lipoxygenase products formation pre-incubated for 15 mins followed by stimulation with A23187 for 10 mins by RP-HPLC based cell based assay2015European journal of medicinal chemistry, Apr-13, Volume: 94Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes.
AID1546376Agonist activity at recombinant human N-terminal epitope tagged/C-terminal eYFP-fused FLAG-tagged GPR84 expressed in Flp-In TREx 293 cell membranes assessed as inhibition of forskolin-induced cAMP production measured after 30 mins by HTRF assay2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID156020Percent of PC-3 cells underwent apoptosis after incubation with 25 uM of compound for 48 hr2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database.
AID1201306Inhibition of human 5-LOX by intact cell based assay2015European journal of medicinal chemistry, Apr-13, Volume: 94Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes.
AID379522Inhibition of thrombin at 50 uM2006Journal of natural products, Nov, Volume: 69, Issue:11
A nitrogen-containing 3-alkyl-1,4-benzoquinone and a gomphilactone derivative from Embelia ribes.
AID1377268Inhibition of GCN5 in Plasmodium falciparum 3D7 assessed as reduction in H3K9 acetylation at 25 uM incubated for 15 mins measured by SDS-PAGE analysis2017European journal of medicinal chemistry, Sep-29, Volume: 138Designing novel inhibitors against histone acetyltransferase (HAT: GCN5) of Plasmodium falciparum.
AID1201316Inhibition of mPGES1 in IL-1beta stimulated human A549 cell microsomal membranes assessed as reduction in PGE2 synthase activity after 15 mins using PGH2 substrate by RP-HPLC method2015European journal of medicinal chemistry, Apr-13, Volume: 94Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes.
AID1140543Inhibition of hexa-His-tagged PAI-1 N152H/K156T/Q321L/M356I mutant (unknown origin) expressed in Escherichia coli BL21(DE3) after 10 mins by uPA-based assay2014Bioorganic & medicinal chemistry letters, May-15, Volume: 24, Issue:10
Design, synthesis, and SAR of embelin analogues as the inhibitors of PAI-1 (plasminogen activator inhibitor-1).
AID276477Binding affinity to recombinant XIAP BIR3 by FP assay2006Bioorganic & medicinal chemistry letters, Nov-15, Volume: 16, Issue:22
Design, synthesis, and characterization of new embelin derivatives as potent inhibitors of X-linked inhibitor of apoptosis protein.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID100530Inhibitory concentration of compound against growth of LNCaP cells in vitro2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database.
AID1447442Agonist activity at human GPR84 assessed as beta-arrestin recruitment by beta-galactosidase complementation assay
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (226)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (5.75)18.7374
1990's9 (3.98)18.2507
2000's21 (9.29)29.6817
2010's139 (61.50)24.3611
2020's44 (19.47)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.42%)5.53%
Reviews14 (5.91%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other222 (93.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research Highlights

Safety/Toxicity (3)

ArticleYear
Embelin attenuates cisplatin-induced nephrotoxicity: Involving inhibition of oxidative stress and inflammation in addition with activation of Nrf-2/Ho-1 pathway.
BioFactors (Oxford, England), Volume: 45, Issue: 3
2019
Embelin (2,5-Dihydroxy-3-undecyl-p-benzoquinone) for photodynamic therapy: study of their cytotoxicity in cancer cells.
Applied biochemistry and biotechnology, Volume: 175, Issue: 2
2015
Toxicity studies with potassium embelate, a new analgesic compound.
Indian journal of experimental biology, Volume: 28, Issue: 3
1990
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (5)

ArticleYear
Antiarthritic effect of chitosan nanoparticle loaded with embelin against adjuvant-induced arthritis in Wistar rats.
IUBMB life, Volume: 72, Issue: 5
2020
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, Volume: 96, Issue: 5
2019
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue: 7
2015
Activation of endothelial nitric oxide synthase by the pro-apoptotic drug embelin: Striking discrepancy between nitric oxide-mediated cyclic GMP accumulation and L-citrulline formation.
Nitric oxide : biology and chemistry, May-15, Volume: 22, Issue: 4
2010
Kinetic fate of potassium embelate, a non-narcotic centrally acting analgesic after oral and intravenous administration.
Pharmacology, Volume: 40, Issue: 3
1990
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (3)

ArticleYear
Embelin-loaded guar gum microparticles for the management of ulcerative colitis.
Journal of microencapsulation, Volume: 35, Issue: 2
2018
Thermosensitive injectable hydrogel enhances the antitumor effect of embelin in mouse hepatocellular carcinoma.
Journal of pharmaceutical sciences, Volume: 103, Issue: 3
2014
Changes in the concentrations of testosterone, luteinising hormone and progesterone associated with administration of embelin.
Contraception, Volume: 44, Issue: 3
1991
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Interactions (1)

ArticleYear
Evaluation of selected Indian medicinal plants for antagonistic potential against Malassezia spp. and the synergistic effect of embelin in combination with ketoconazole.
Microbial pathogenesis, Volume: 110
2017
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]